Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Acq. announced
Quarterly results
Auditor change
Appointed director
CC transcript
Director departure
SEELOS THERAPEUTICS, INC. (APRI) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/31/2018 8-K Quarterly results
Docs: "Press Release"
08/09/2018 8-K Quarterly results
Docs: "Apricus Biosciences Provides Corporate Update and Second Quarter 2018 Financial Results Company Enters Into Merger Agreement with Seelos Therapeutics, Inc. Apricus Shareholders Expected to Own ~14% of Combined Company Based on Estimated $90 Million Valuation at Closing Merger Expected to Close in Fourth Quarter 2018 SAN DIEGO, CA, August 9, 2018 -- Apricus Biosciences, Inc. , a biopharmaceutical company historically focused on seeking to advance innovative medicines in urology and rheumatology, today reported financial results for the second quarter and first half of 2018 and provided a corporate update on its near-term priorities. On July 30, 2018, the Company announced the signing of a definitive agreement to merge with Seelos Therapeutics, Inc., a privately-held biotechnology company, i..."
05/03/2018 8-K Quarterly results
Docs: "Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results Company Pursuing U.S. Vitaros Partnership and Strategic Alternatives"
03/01/2018 8-K Quarterly results
Docs: "Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Company Expects to Submit Vitaros End of Review Meeting Request This Month Vitaros End-of-Review Meeting Expected to Occur in April 2018 Company Expects Cash Runway Through 2018 Conference Call / Webcast Today, March 1, 2018 at 4:30 p.m. ET"
11/02/2017 8-K Quarterly results
Docs: "Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results Vitaros U.S. NDA Resubmission Review Remains on Track PDUFA Goal Date of February 17, 2018 Conference Call / Webcast Today, November 2, 2017 at 4:30 p.m. ET"
08/02/2017 8-K Quarterly results
05/11/2017 8-K Form 8-K - Current report
03/13/2017 8-K Form 8-K - Current report
11/08/2016 8-K Quarterly results
Docs: "Apricus Biosciences Provides Corporate Update and Third Quarter Financial Results Strategic Focus on Growing Global Vitaros ® Revenue and Achieving Profitability in 2017 Apricus Granted Type B Meeting with FDA to Discuss the Vitaros ® U.S. NDA Re-Submission Conference Call / Webcast Today, Tuesday, November 8, 2016 at 4:30 p.m. ET"
05/09/2016 8-K Quarterly results
Docs: "Apricus Biosciences Provides Corporate Update and First Quarter Financial Results"
03/09/2016 8-K Form 8-K - Current report
11/05/2015 8-K Quarterly results
Docs: "Apricus Biosciences Provides Corporate Update and Third Quarter 2015 Financial Results Company Continues to Advance Clinical Pipeline Vitaros Quarterly Unit Sales Increased 146% in Europe Conference Call / Webcast Today, Thursday, November 5, 2015 at 5:00 p.m. ET"
08/05/2015 8-K Quarterly results
Docs: "APRICUS BIOSCIENCES PROVIDES CORPORATE UPDATE AND SECOND QUARTER 2015 FINANCIAL RESULTS"
05/11/2015 8-K Quarterly results
Docs: "APRICUS BIOSCIENCES PROVIDES CORPORATE UPDATE AND FIRST QUARTER 2015 FINANCIAL RESULTS"
03/16/2015 8-K Quarterly results
Docs: "APRICUS BIOSCIENCES PROVIDES CORPORATE UPDATE AND 2014 YEAR-END FINANCIAL RESULTS"
08/12/2014 8-K Quarterly results
Docs: "Opinion of Brownstein Hyatt Farber Schreck, LLP",
"Common Stock Purchase Agreement, by and between Apricus Bioscience, Inc. and Aspire Capital Fund, LLC",
"Registration Rights Agreement, by and between Apricus Biosciences, Inc. and Aspire Capital Fund, LLC",
"APRICUS BIOSCIENCES ENTERS INTO COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL",
"Apricus Biosciences Provides Corporate Update and Second Quarter 2014 Financial Results"
03/08/2011 8-K Form 8-K - Current report
11/14/2007 8-K Form 8-K - Current report
08/14/2007 8-K Form 8-K - Current report
05/10/2007 8-K Form 8-K - Current report
11/09/2006 8-K Form 8-K - Current report
08/09/2006 8-K Form 8-K - Current report
05/09/2006 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy